Sloy Dahl & Holst LLC boosted its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 18.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,492 shares of the company’s stock after purchasing an additional 2,079 shares during the period. Sloy Dahl & Holst LLC’s holdings in ARK Genomic Revolution ETF were worth $443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Operose Advisors LLC acquired a new position in shares of ARK Genomic Revolution ETF in the third quarter worth about $25,000. Stephens Consulting LLC acquired a new position in shares of ARK Genomic Revolution ETF in the third quarter worth about $28,000. Allworth Financial LP raised its position in shares of ARK Genomic Revolution ETF by 65.3% in the third quarter. Allworth Financial LP now owns 1,425 shares of the company’s stock worth $40,000 after acquiring an additional 563 shares during the period. High Net Worth Advisory Group LLC raised its position in shares of ARK Genomic Revolution ETF by 80.9% in the first quarter. High Net Worth Advisory Group LLC now owns 1,118 shares of the company’s stock worth $51,000 after acquiring an additional 500 shares during the period. Finally, BKM Wealth Management LLC acquired a new position in shares of ARK Genomic Revolution ETF in the fourth quarter worth about $78,000.
ARK Genomic Revolution ETF Stock Performance
Shares of ARK Genomic Revolution ETF stock traded down $0.79 during trading hours on Wednesday, reaching $24.11. The stock had a trading volume of 3,718,870 shares. The company’s fifty day simple moving average is $29.19 and its 200 day simple moving average is $28.53.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Read More
- Five stocks we like better than ARK Genomic Revolution ETF
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Abbott Laboratories Outlook is Healthy: Buy the Dip
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- ASML Fires Warning Shot For Tech Investors
- How to Calculate Inflation Rate
- Prologis Stock Leading U.S. Logistics Boom
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
